Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pola-R2 in Newly-diagnosed Non-fit Elderly DLBCL
NCT06176729Phase 2Recruiting
- Start
- Oct 2023
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL). Started Oct 2023; status: recruiting.
02
Drugs
polatuzumab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06176729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06176729.